Overview

  • Product name

    Momelotinib (CYT387), ATP-competitve JAK 1/2 selective inhibitor
  • Description

    Potent ATP-competitve JAK 1/2 selective inhibitor
  • Alternative names

    • CYT387
  • Biological description

    Potent ATP-competitive JAK 1/2 selective inhibitor (IC50 values are 11, 18 and 155 nM for JAK1, JAK2 and JAK3 respectively). Shows antiproliferative effects (IC50 = 4 μM, IL-3 stimulated Ba/F3 cells). Shows antitumor effects in vivo.
  • Purity

    > 95%
  • CAS Number

    1056634-68-4
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Zhu Z  et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4:452-65 (2014). Read more (PubMed: 24444711) »
  • Monaghan KA  et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 25:1891-9 (2011). Read more (PubMed: 21788946) »
  • Tyner JW  et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115:5232-40 (2010). Read more (PubMed: 20385788) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141372.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up